Merck KGaA to buy Silence Therapeutics for $1.3 billion

Germany's Merck KGaA is acquiring U.K.-based Silence Therapeutics, a gene-silencing biotech, for approximately $1.3 billion to add the experimental drug divesiran for rare disease polycythemia vera to its pipeline, with the deal expected to complete in early 2027.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.